



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMER United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450

APPLICATION N	O	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/971,774		10/09/2001	H. Paul Redmond	1194-180 3168	
6449	7590	04/06/2004		EXAMINER	
ROTHW	ELL, FIG	G, ERNST & MAN	MAIER, LEIGH C		
	rreet, N.	W.		ART UNIT	PAPER NUMBER
SUITE 80	0			ART UNIT	THE ENTY OF THE ENTY
WASHINGTON, DC 20005				1623	
			DATE MAILED: 04/06/2004		

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)				
		09/971,774	REDMOND ET AL.				
	Office Action Summary	Examiner	Art Unit				
		Leigh C. Maier	1623				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply							
A SHO THE I - Exter after - If the - If NO - Failur Any r	ORTENED STATUTORY PERIOD FOR REPLY MAILING DATE OF THIS COMMUNICATION. This is not firm may be available under the provisions of 37 CFR 1.13 SIX (6) MONTHS from the mailing date of this communication. The period for reply specified above is less than thirty (30) days, a reply a period for reply is specified above, the maximum statutory period we re to reply within the set or extended period for reply will, by statute, reply received by the Office later than three months after the mailing and patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a reply be time within the statutory minimum of thirty (30) days will apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).				
Status							
2a)⊠ 3)□	Responsive to communication(s) filed on <u>24 December 2003</u> . This action is FINAL . 2b) This action is non-final. Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.						
Dispositi	on of Claims						
5)□ 6)⊠ 7)□ 8)□	/ <u> </u>						
	·						
9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) accepted or b) objected to by the Examiner.							
, —	Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.							
Priority u	nder 35 U.S.C. § 119						
 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 							
Attachment	e of References Cited (PTO-892)	4) Interview Summary	(PTO-413)				
2) Notice 3) Inform	e of Neierences Cited (PTO-692) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449 or PTO/SB/08) No(s)/Mail Date	Paper No(s)/Mail Da					

Art Unit: 1623

DETAILED ACTION

Status of the Claims

Claims 1-12 and 26 are pending.

Claim Rejections - 35 U.S.C. § 103

Claims 1-5, 8, 9, 11, and 12 are again rejected under 35 U.S.C. 103(a) as being unpatentable over JACOBI et al (Langenbecks Arch. Chir., 1997) in view of MONSON et al (WO 92/00743), as set forth in the previous Office action.

Claims 1-12 are rejected under 35 U.S.C. 103(a) as being unpatentable over JACOBI et al (Langenbecks Arch. Chir., 1997) in view of MONSON et al (WO 92/00743) and further in view of ALLGOOD et al (US 5,176,651).

Claims 1-5, 8, 9, 11, and 12 are rejected under 35 U.S.C. 103(a) as being unpatentable over JACOBI et al (Langenbecks Arch. Chir., 1997) in view of MONSON et al (WO 92/00743) and further in view of NICOLSON et al (US 5,262,403).

Claims 1-5, 8, 9, 11, 12, and 26 is rejected under 35 U.S.C. 103(a) as being unpatentable over JACOBI et al (Langenbecks Arch. Chir., 1997) in view of MONSON et al (WO 92/00743) and further in view of PHYSICIANS' DESK REFERENCE (PDR - 1995).

The invention is as set forth in the previous Office action. Applicant's arguments filed December 24, 2003 have been fully considered but they are not persuasive. The arguments will be addressed as a group, as Applicant has not argued them separately.

Art Unit: 1623

Applicant first contends that JACOBI does not teach each and every step of the present claims. As the rejection is one of obviousness, this was clearly stated in the previous Office action.

With regard to the combination of JACOBI and MONSON, Applicant alleges hindsight reasoning by the examiner. It must be recognized that any judgment on obviousness is in a sense necessarily a reconstruction based upon hindsight reasoning. But so long as it takes into account only knowledge which was within the level of ordinary skill at the time the claimed invention was made, and does not include knowledge gleaned only from the Applicant's disclosure, such a reconstruction is proper. See *In re McLaughlin*, 443 F.2d 1392, 170 USPQ 209 (CCPA 1971). The reasoning is repeated below.

It would have been obvious to one having ordinary skill in the art at the time the invention was made to administer a solution of taurolidine and/or taurultam (with or without heparin) during laparoscopic cancer surgery, as JACOBI had taught that the intraperitoneal adminstration of taurolidine or a combination of taurolidine and heparin at the time of laparoscopic surgery for tumor removal reduces the incidence of tumor growth and trocar metastases. MONSON had taught that these species (taurolidine and/or taurultam) are functional equivalents for the inhibition of metastases. In the absence of unexpected results, one of ordinary skill would reasonably expect success in the use of taurolidine and/or taurultam for this art-disclosed utility. It would be within the scope of the artisan to optimize the solution concentration with routine experimentation. With regard to the use of a trocar, the reference is drawn to the decreased incidence of trocar metastases, so the use of this instrument is clearly implied.

Art Unit: 1623

It would have been obvious to one having ordinary skill in the art at the time the invention was made to administer a solution of taurolidine and/or taurultam before and/or after cancer surgery for the benefits of treating malignancies as well as prevention of metastases, taught by MONSON. In the absence of unexpected results, it would be further obvious to use this procedure for all of the recited cancers with a reasonable expectation of success. It would be within the scope of the artisan to select any common type of administration, such as IV or catheter, to administer the solution.

In addressing the other references, Applicant appears to be arguing that the references are merely general discussions of broad topics, whereas each reference was cited for very specific teachings that allowed their combination with JACOBI and MONSON.

Applicant further contends that none of the references can be combined with JACOBI and MONSON to suggest the instant invention. However, Applicant neglects to provide any reasoning as to why the combinations are deficient.

THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event,

Art Unit: 1623

however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Examiner's hours, phone & fax numbers

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Leigh Maier whose telephone number is (571) 272-0656. The examiner can normally be reached on Tuesday, Wednesday, and Friday 7:00 to 3:30 (ET).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mr. James O. Wilson (571) 272-0661, may be contacted. The fax number for Group 1600, Art Unit 1623 is (703) 308-4556 or 305-3592.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Technology Center 1600 receptionist whose telephone number is (703) 308-1235.

Visit the U.S. PTO's site on the World Wide Web at http://www.uspto.gov. This site contains lots of valuable information including the latest PTO fees, downloadable forms, basic search capabilities and much more.

JAMES O. WILSON SUPERVISORY PATENT EXAMINER JECHNOLOGY CENTER 1600

Leigh C. Maier Patent Examiner March 26, 2004